LONDON: AstraZeneca PLC announces that, on 3 August 2020, it priced a three tranche global bond offering totalling $3bn.
The offering is expected to close on 6 August 2020, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes, which may include the refinancing of existing indebtedness.
The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of the following three tranches:
- $1.2bn of fixed rate notes with a coupon of 0.700%, maturing 8 April 2026;
- $1.3bn of fixed rate notes with a coupon of 1.375%, maturing 6 August 2030; and
- $0.5bn of fixed rate notes with a coupon of 2.125%, maturing 6 August 2050.
BofA Securities, Inc., HSBC Securities (USA) Inc. and Mizuho Securities USA LLC acted as joint book-running managers on the transaction and Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley and Co. LLC acted as co-managers on the transaction.
The notes will be issued under AstraZeneca’s effective shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 8 November 2019. The offering is being made solely by means of the prospectus contained within that shelf-registration statement, along with a prospectus supplement forming part of the effective registration statement, which investors should read.
The bond issuance does not impact the Company’s financial guidance for 2020.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Leave a Reply